• Alternariol Induces Hepatic Stellate Cell Fibrosis via Omics

  2026-06-21

  The referenced study provides the first omics-based mechanistic evidence that Alternariol (AOH) and related Alternaria toxins directly induce hepatic stellate cell (LX-2) transdifferentiation into myofibroblasts, implicating these mycotoxins in liver fibrosis. This work maps the molecular signaling cascades involved and proposes a CotA laccase-based detoxification strategy, advancing both mycotoxin research and potential mitigation approaches.

• Sulfachloropyridazine Modulates Cecal Microbiota in Eimeria-

  2026-06-20

  This study investigates how sulfachlorpyridazine, alone and combined with ethanamizuril, alters the cecal microbiota and metabolome in chickens infected with Eimeria tenella. Through integrated microbiome and metabolomics analyses, the research reveals agent-specific effects on microbial community structure and functional metabolites, informing future protocols for managing avian coccidiosis and microbiome-associated disease.

• U0126: Selective MEK1/2 Inhibitor for Precision MAPK/ERK Con

  2026-06-19

  U0126 is a potent, cell-permeable MEK1/2 inhibitor used to dissect MAPK/ERK signaling. It exhibits nanomolar IC50s, blocks ERK1/2 phosphorylation, and is pivotal for studies in neurodegeneration and cancer biology.

• Temafloxacin in Synergy and Resistance Research: Next-Gen In

  2026-06-19

  Explore the advanced roles of Temafloxacin, a fluoroquinolone broad-spectrum antibacterial agent, in both synergy testing and antibiotic resistance research. Discover how leveraging MIC synergy data and intracellular bactericidal assays expands the compound's utility for innovative antibacterial workflows.

• Tetramethylrhodamine Ethyl Ester Perchlorate in Mitochondria

  2026-06-18

  Tetramethylrhodamine ethyl ester perchlorate (TMRE) sets the standard for sensitive, quantitative live-cell mitochondrial membrane potential assays. Its robust fluorescence and low cytotoxicity empower researchers to dissect mitochondrial dynamics and dysfunction with precision across diverse biological models.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Use and Protocol G

  2026-06-18

  2-Hydroxypropyl-β-cyclodextrin (SKU B6413) addresses the persistent challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those containing aromatic or phenyl groups—in pharmaceutical and biochemical research. It is validated for roles as a solubility enhancer or drug formulation excipient, but applications outside these parameters are not supported by current documentation.

• METTL14-m6A Regulation in Ulcerative Colitis: DHRS4-AS1/miR-

  2026-06-17

  A recent study reveals that METTL14, a key m6A methyltransferase, protects against colonic inflammation in ulcerative colitis by regulating the lncRNA DHRS4-AS1 and its downstream miR-206/A3AR axis. This mechanistic insight advances understanding of epigenetic modulation in inflammatory bowel disease and highlights potential molecular targets for future therapeutic strategies.

• Angiotensin I: Decoding Mechanism, Strategy, and Translation

  2026-06-17

  This thought-leadership article explores the mechanistic depth, experimental strategies, and translational implications of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) in cardiovascular and neuroendocrine research. By integrating recent evidence, protocol insights, and a competitive landscape analysis, it provides actionable guidance for translational researchers seeking to harness APExBIO’s Angiotensin I (human, mouse, rat) for next-generation discovery and drug development.

• Bacterial OMVs Enable Rapid mRNA Antigen Display for Tumor V

  2026-06-16

  This study introduces an engineered bacterial outer membrane vesicle (OMV) platform that rapidly and efficiently displays mRNA antigens for personalized tumor vaccination. The approach demonstrates significant antitumor efficacy and immune memory, offering a distinct alternative to lipid nanoparticles for mRNA delivery.

• Marein Restores Mitoxantrone Sensitivity via ABCG2 Inhibitio

  2026-06-16

  The referenced study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 transporter that restores chemosensitivity in drug-resistant cancer cells. This discovery provides a mechanistic basis for overcoming multidrug resistance to agents like Mitoxantrone, with implications for the design of combination therapies in oncology.

• Translating Sulfamonomethoxine: Mechanisms, Models, and Impa

  2026-06-15

  This thought-leadership article unpacks Sulfamonomethoxine’s (SMM) mechanistic underpinnings as a veterinary and aquaculture antibiotic, integrating environmental, translational, and competitive perspectives. It offers actionable, evidence-based guidance for researchers aiming to leverage SMM in antimicrobial resistance, toxicity, and animal health models, while highlighting APExBIO’s product advantages.

• IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Studie

  2026-06-15

  IWP-L6 empowers researchers with sub-nanomolar Porcupine inhibition to dissect Wnt signaling in developmental, metabolic, and regenerative contexts. Its exceptional potency, workflow adaptability, and reliable supply from APExBIO set a new standard for reproducible, high-fidelity Wnt pathway research.

• DRD4 Drives Chemo-Resistance via Akt/β-Catenin in Liver Canc

  2026-06-14

  This study uncovers a pivotal role for DRD4 in promoting chemo-resistance and cancer stem cell-like phenotypes in hepatocellular carcinoma by activating the PI3K/Akt/β-catenin signaling axis. The findings highlight DRD4 as a mechanistically distinct target for overcoming multidrug resistance and improving therapy outcomes in liver cancer.

• Doxycycline Hyclate: Matrix Metalloproteinases Inhibitor in

  2026-06-13

  Doxycycline hyclate enables precise inhibition of MMP-2 and MMP-9, preserving blood-brain barrier integrity in neurotoxic and inflammatory models. Its robust solubility and validated in vivo efficacy make it a first-line tool for dissecting neurovascular mechanisms and evaluating protective strategies.

• Nullscript: Advanced HDAC Inhibition for Translational Resea

  2026-06-12

  Explore Nullscript, a distinctive histone deacetylase inhibitor, in the context of translational research. This article delves deeper into its mechanistic nuances, unique inactivity in transcriptional facilitation, and the implications for cardiac and neurodegenerative disease assays.

453 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page